mecbotamab vedotin

Generic: BA3011·Code: BA3011

mecbotamab vedotin: developed by 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

BioAtla, Inc. (BCAB)

What it means

Source-backed records connect mecbotamab vedotin to BCAB; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could mecbotamab vedotin → BCAB affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Head and Neck Cancer Ovarian Cancer

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)

Company	Phase	Indication
BioAtla, Inc. (BCAB) Head and Neck Cancer	Phase 2	Head and Neck Cancer
BioAtla, Inc. (BCAB) Head and Neck Cancer	Phase 2	Head and Neck Cancer

Clinical Trials (1)

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

NCT04918186·Phase 2

Recruiting

Primary endpoint: To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trials

Interventionalopen60 targetStarted 2022-05Completion 2026-126 sites · Canada, United StatesCanadian Cancer Trials Group

mecbotamab vedotin

Related indications

Study sponsors

Frequently asked questions

Who is developing mecbotamab vedotin?

How many clinical trials involve mecbotamab vedotin?